Crossmark

Optimizing imatinib sampling strategies through a population approach: a crucial step to model-informed precision dosing validation for point-of-care therapeutic drug monitoring

Crossref DOI link: https://doi.org/10.1186/s40360-026-01181-5

Published Online: 2026-07-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pétermann, Yuan J.

Chen, Junrui

Alberi, Lavinia

Alexandra, Simon

Veuve, François

Choong, Eva

Thoma, Yann

Rigamonti, Roberto

Carvalho, Bruno Da Rocha

Carrara, Sandro

Girardin, François R.

Buclin, Thierry

Csajka, Chantal

Guidi, Monia
Funding

Funding for this research was provided by:

University of Lausanne
License Information

Text and Data Mining valid from 2026-07-07

Accepted Manuscript valid from 2026-07-07
More Information

Article History

Received: 28 April 2026

Accepted: 1 July 2026

First Online: 7 July 2026

Declarations

:

: The study was approved by the ethics committee ”Cantonal Ethics Committee for Human Research of the Canton of Vaud” (CER-VD, project number: 2024-01723) and was conducted in accordance with the Declaration of Helsinki. Informed consent to participate was obtained from all included patients via the institutional general consent framework of the Lausanne University Hospital (CHUV).

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below